User login
Credit: Aaron Logan
SAN DIEGO—Researchers have found evidence to suggest there may be little difference between an immune response that kills cancer cells and one that stimulates tumor growth.
The team set out to determine whether the immune responses that mediate cancer immunosurveillance and those responsible for inflammatory facilitation are qualitatively or quantitatively distinct.
They tested antibodies in mouse models of a few different cancers, including rituximab in Burkitt lymphoma.
And they found that lower antibody concentrations stimulated tumor growth, while higher concentrations inhibited growth, and the dose range was “surprisingly narrow.”
The researchers reported these findings in a paper published in PNAS and a poster presentation at the AACR Annual Meeting 2014 (abstract 1063).
“We have found that the intensity difference between an immune response that stimulates cancer and one that kills it may not be very much,” said principal investigator Ajit Varki, MD, of the University of California, San Diego School of Medicine.
“This may come as a surprise to researchers exploring two areas typically considered distinct: the role of the immune system in preventing and killing cancers and the role of chronic inflammation in stimulating cancers. As always, it turns out that the immune system is a double-edged sword.”
The concept of naturally occurring immunosurveillance against malignancies is not new, and there is compelling evidence for it. But understanding this process is confounded by the fact that some types of immune reaction promote tumor development.
Dr Varki and his colleagues looked specifically at a non-human sialic acid sugar molecule called Neu5Gc. Previous research showed that Neu5Gc accumulates in human tumors from dietary sources, despite an ongoing antibody response against it.
The researchers deployed antibodies against Neu5Gc in a mouse tumor model to determine whether and to what degree the antibodies altered tumor progression. The team found that low antibody doses stimulated growth, but high doses inhibited it.
The effect occurred over a “linear and remarkably narrow range,” according to Dr Varki, generating an immune response curve or “inverse hormesis.” Moreover, this curve could be shifted to the left or right simply by modifying the quality of the immune response.
The researchers uncovered similar findings in experiments with mouse models of colon and lung cancer, as well as when they used rituximab in a model of Burkitt lymphoma.
Dr Varki said these results could have implications for all aspects of cancer research. The immune response can have multiple roles in the genesis of cancers, in altering the progress of established tumors and in anticancer therapies that use antibodies as drugs.
Dr Varki is a co-founder of the company Sialix, Inc., which has licensed UC San Diego technologies related to anti-Neu5Gc antibodies in cancer. 
Credit: Aaron Logan
SAN DIEGO—Researchers have found evidence to suggest there may be little difference between an immune response that kills cancer cells and one that stimulates tumor growth.
The team set out to determine whether the immune responses that mediate cancer immunosurveillance and those responsible for inflammatory facilitation are qualitatively or quantitatively distinct.
They tested antibodies in mouse models of a few different cancers, including rituximab in Burkitt lymphoma.
And they found that lower antibody concentrations stimulated tumor growth, while higher concentrations inhibited growth, and the dose range was “surprisingly narrow.”
The researchers reported these findings in a paper published in PNAS and a poster presentation at the AACR Annual Meeting 2014 (abstract 1063).
“We have found that the intensity difference between an immune response that stimulates cancer and one that kills it may not be very much,” said principal investigator Ajit Varki, MD, of the University of California, San Diego School of Medicine.
“This may come as a surprise to researchers exploring two areas typically considered distinct: the role of the immune system in preventing and killing cancers and the role of chronic inflammation in stimulating cancers. As always, it turns out that the immune system is a double-edged sword.”
The concept of naturally occurring immunosurveillance against malignancies is not new, and there is compelling evidence for it. But understanding this process is confounded by the fact that some types of immune reaction promote tumor development.
Dr Varki and his colleagues looked specifically at a non-human sialic acid sugar molecule called Neu5Gc. Previous research showed that Neu5Gc accumulates in human tumors from dietary sources, despite an ongoing antibody response against it.
The researchers deployed antibodies against Neu5Gc in a mouse tumor model to determine whether and to what degree the antibodies altered tumor progression. The team found that low antibody doses stimulated growth, but high doses inhibited it.
The effect occurred over a “linear and remarkably narrow range,” according to Dr Varki, generating an immune response curve or “inverse hormesis.” Moreover, this curve could be shifted to the left or right simply by modifying the quality of the immune response.
The researchers uncovered similar findings in experiments with mouse models of colon and lung cancer, as well as when they used rituximab in a model of Burkitt lymphoma.
Dr Varki said these results could have implications for all aspects of cancer research. The immune response can have multiple roles in the genesis of cancers, in altering the progress of established tumors and in anticancer therapies that use antibodies as drugs.
Dr Varki is a co-founder of the company Sialix, Inc., which has licensed UC San Diego technologies related to anti-Neu5Gc antibodies in cancer.
Credit: Aaron Logan
SAN DIEGO—Researchers have found evidence to suggest there may be little difference between an immune response that kills cancer cells and one that stimulates tumor growth.
The team set out to determine whether the immune responses that mediate cancer immunosurveillance and those responsible for inflammatory facilitation are qualitatively or quantitatively distinct.
They tested antibodies in mouse models of a few different cancers, including rituximab in Burkitt lymphoma.
And they found that lower antibody concentrations stimulated tumor growth, while higher concentrations inhibited growth, and the dose range was “surprisingly narrow.”
The researchers reported these findings in a paper published in PNAS and a poster presentation at the AACR Annual Meeting 2014 (abstract 1063).
“We have found that the intensity difference between an immune response that stimulates cancer and one that kills it may not be very much,” said principal investigator Ajit Varki, MD, of the University of California, San Diego School of Medicine.
“This may come as a surprise to researchers exploring two areas typically considered distinct: the role of the immune system in preventing and killing cancers and the role of chronic inflammation in stimulating cancers. As always, it turns out that the immune system is a double-edged sword.”
The concept of naturally occurring immunosurveillance against malignancies is not new, and there is compelling evidence for it. But understanding this process is confounded by the fact that some types of immune reaction promote tumor development.
Dr Varki and his colleagues looked specifically at a non-human sialic acid sugar molecule called Neu5Gc. Previous research showed that Neu5Gc accumulates in human tumors from dietary sources, despite an ongoing antibody response against it.
The researchers deployed antibodies against Neu5Gc in a mouse tumor model to determine whether and to what degree the antibodies altered tumor progression. The team found that low antibody doses stimulated growth, but high doses inhibited it.
The effect occurred over a “linear and remarkably narrow range,” according to Dr Varki, generating an immune response curve or “inverse hormesis.” Moreover, this curve could be shifted to the left or right simply by modifying the quality of the immune response.
The researchers uncovered similar findings in experiments with mouse models of colon and lung cancer, as well as when they used rituximab in a model of Burkitt lymphoma.
Dr Varki said these results could have implications for all aspects of cancer research. The immune response can have multiple roles in the genesis of cancers, in altering the progress of established tumors and in anticancer therapies that use antibodies as drugs.
Dr Varki is a co-founder of the company Sialix, Inc., which has licensed UC San Diego technologies related to anti-Neu5Gc antibodies in cancer.